6 hours ABBV’s Newly Added Parkinson’s Disease Drug Meets Second Study Goal Zacks
Data from a late-stage study shows that AbbVie’s tavapadon reduced the burden of Parkinson’s disease. The drug previously demonstrated efficacy as adjunctive therapy.
Data from a late-stage study shows that AbbVie’s tavapadon reduced the burden of Parkinson’s disease. The drug previously demonstrated efficacy as adjunctive therapy.